The progression of the antibody, initially designated as MORAb-004, represents a notable endeavor in antibody therapy. The team at its developers started research on the humanized monoclonal immunoglobulin targeting CD3, with the objective of activating immune cells to eliminate cancer entities. Preliminary investigational assessments revealed pote